Biotechnological Potential of Thymus sipyleus Boiss. subsp. sipyleus Extract in the Inhibition of Some Metabolic Enzyme Activities
Öz
Thymus sipyleus Boiss. subsp. sipyleus, a plant widely used in traditional medicine, holds substantial promise in the biotechnological field due to its bioactive compounds. This study explores the inhibitory effects of Thymus sipyleus Boiss. subsp. sipyleus extract on six major enzymes—acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), lipoxygenase (LOX), α-amylase, tyrosinase, and xanthine oxidase (XO)—which are critical in various pathological processes such as neurodegenerative diseases, metabolic disorders, and skin pigmentation issues. Through advanced enzymatic assays, we demonstrate the extract’s potent inhibitory activity, especially against AChE and BuChE, which are relevant targets in Alzheimer’s therapy, and LOX, implicated in inflammatory diseases. Among the three different extracts tested (water, methanol, and ethanol), the methanol extract exhibited the highest enzyme inhibitory activities, with inhibition rates of 46.23% for LOX, 42.05% for AChE, 38.27% for BuChE, 36.26% for XO, 33.71% for α-amylase, and 26.93% for tyrosinase. The ethanol extract followed with slightly lower but comparable results (AChE: 40.29%, BuChE: 37.64%, LOX: 43.32%), while the water extract showed the lowest inhibitory activity across all enzymes tested (AChE: 38.22%, BuChE: 34.78%, LOX: 40.3%). Although none of the extracts matched the effectiveness of standard inhibitors, their moderate to strong activity indicates substantial therapeutic potential. The results highlight the biotechnological potential of Thymus sipyleus Boiss. subsp. sipyleus extract as a natural source for the development of enzyme-specific inhibitors. The findings suggest that this plant can serve as a sustainable, plant-based alternative for producing bioactive compounds, thereby contributing to the design of novel therapeutic strategies in biotechnology, including neuroprotective, anti-inflammatory, and anti-diabetic treatments.
Anahtar Kelimeler
enzyme inhibition, plant-based therapeutics, sustainable drug development
Etik Beyan
The author declares that this study complies with Research and Publication Ethics.
Kaynakça
- Abd El-Rahman, H. S., & Abd-ELHak, N. A. (2015). Xanthine oxidase inhibitory activity and antigout of celery, leek, parsley, and molokhia. Advances in Biochemistry, 3(4), 40–50. https://doi.org/10.11648/j.ab.20150304.11
- Ağalar, H. G., Kürkçüoğlu, M., Başer, K. H. C., & Turgut, K. (2021). Volatile constituents of three Thymus sipyleus Boiss. subspecies from different sites in Turkey. Turkish Journal of Chemistry, 45(6), Article 24. https://doi.org/10.3906/kim-2103-6
- Chaachouay, N., & Zidane, L. (2024). Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs and Drug Candidates, 3(1), 184-207. https://doi.org/10.3390/ddc3010011
- Chang, T. S. (2009). An updated review of tyrosinase inhibitors. International Journal of Molecular Sciences, 10(6), 2440–2475. https://doi.org/10.3390/ijms10062440
- Colović, M. B., Krstić, D. Z., Lazarević-Pašti, T. D., Bondžić, A. M., & Vasić, V. M. (2013). Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current Neuropharmacology, 11(3), 315–335. https://doi.org/10.2174/1570159X11311030006
- Dawson, J., & Walters, M. (2006). Uric acid and xanthine oxidase: Future therapeutic targets in the prevention of cardiovascular disease? British Journal of Clinical Pharmacology, 62(6), 633–644. https://doi.org/10.1111/j.1365-2125.2006.02785.x
- Ellman, G. L., Courtney, K. D., Andres, V., Jr., & Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7, 88–95. https://doi.org/10.1016/0006-2952(61)90145-9
- Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q. S., Mamczarz, J., Holloway, H. W., Giordano, T., Chen, D., Furukawa, K., Sambamurti, K., Brossi, A., & Lahiri, D. K. (2005). Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America, 102(47), 17213–17218. https://doi.org/10.1073/pnas.0508575102
- Guerrero, L., Castillo, J., Quiñones, M., Garcia-Vallvé, S., Arola, L., Pujadas, G., & Muguerza, B. (2012). Inhibition of angiotensin-converting enzyme activity by flavonoids: Structure-activity relationship studies. PLoS ONE, 7(11), e49493. https://doi.org/10.1371/journal.pone.0049493
- Jasiecki, J., Targońska, M., & Wasąg, B. (2021). The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer’s Disease Pathogenesis. International Journal of Molecular Sciences, 22(4), 2033. https://doi.org/10.3390/ijms22042033